Anchor
Fatty liver disease linked to higher cardiovascular risk in large cohort studies
New CapabilitiesNew 318,000-person study reports 2.5× risk, adding to five years of concordant evidence
Today: 318,000-person study reports 2.5× cardiovascular riskNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated 54 minutes agoA study of 318,000 people reported this week found that subclinical fatty liver disease is linked to roughly 2.5 times higher cardiovascular risk. It is the latest in a five-year run of large cohort studies showing the same pattern.
About 30-40% of US adults have fatty liver, most without symptoms. The evidence is pushing cardiologists and hepatologists to ask whether liver assessment belongs in standard heart risk screening, alongside cholesterol and blood pressure.
Why it matters
If liver fat independently drives heart attacks, routine liver assessment could reshape cardiovascular screening for tens of millions of Americans.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
2.5×
Reported cardiovascular risk increase
From the 318,000-person study reported September 2026, comparing subclinical liver disease against no liver disease.
318,000
Participants in the new study
The largest cohort to date examining subclinical liver disease and cardiovascular outcomes.
1.63
Adjusted MACE hazard ratio, biopsy-confirmed NAFLD
Swedish nationwide histology cohort: 10,422 patients vs 46,517 matched controls, median 13.6 years follow-up.
30-40%
US adults with fatty liver disease
Prevalence estimate cited by Mass General Brigham researchers from the PROMISE trial analysis.
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict.
Log in
Sign Up
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Example
Anchor
EU tariff revenue
$52B
Big for this kind of number
Mystery
Pentagon AI contract
?
Round 1
Streak: 0
Mystery
?
Keyboard: ↓/L lower · ↑/H higher
0 pts
Best streak: 0 · Rounds: 0
0 points — sign up to put that on the leaderboard.
Now try on this story
Timeline
Fatty liver disease linked to higher cardiovascular risk in large cohort studies
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Loading puzzle…
Tap 💡 Free hint to lock the oldest into slot 1 — that leaves just four to order. Type pills are clues.
0/5
Exact slot
0/5
Within 1
Sign up to save your score and track a streak across stories.
Now try on this story
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Loading today's puzzle…
0/4 groups
Mistakes
Sign up to keep a daily streak — a new puzzle lands every day.
Now try on this story
Exit debate?
Your progress in this debate will be lost.
How it works
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
SIDE A (PRO)
Select debater for this side:
No debate personas available right now.
SIDE B (CON)
Select debater for this side:
No debate personas available right now.
VS
Get ready to make your prediction...
Round of
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Your Crossfire Question
Generating arguments...
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Correct predictions earn +20 XP
· Press 1 or 2 to pick
Evidence
40%
Logic
30%
Detail
20%
Style
10%
Round Results
Your Pick
Not this time
(%)
Overall Score
/10
Your Pick
Not this time
(%)
Overall Score
/10
Set the Crossfire
Pick the question both personas must answer in the final round
Crafting crossfire questions...
Choosing a question earns +10 XP crossfire bonus
🏆
Total XP Earned
Cred Change
Predictions
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Base completion
+20 XP
Rounds played ( rounds x 5 XP)
+ XP
Correct predictions ( correct x 20 XP)
+ XP
Crossfire bonus
+10 XP
Accuracy
%
Prediction History
Round
You picked:
✓
✗
Now try on this story
Keep debating to level up your credibility and unlock achievements
People Involved
Organizations Involved
MG
Mass General Brigham Heart and Vascular Institute
Research hospital institute
Published PROMISE trial analysis linking hepatic steatosis to coronary plaque and events
Boston-based research institute that analyzed cardiac CT scans from 3,637 PROMISE trial participants.
UK Biobank
Biomedical research cohort
Provided MRI liver imaging data for the liver-CVD association studies
UK longitudinal cohort of 500,000 participants; its imaging sub-study measured liver disease activity with LiverMultiScan MRI.
Timeline
November 2021 September 2026
6 events
Latest: Today
Tap a bar to jump to that date
-
318,000-person study reports 2.5× cardiovascular risk
Today Research PublicationLarge cohort links subclinical liver disease to about 2.5 times higher cardiovascular risk, reported on r/science.
-
Mass General Brigham links fatty liver to rupture-prone plaque
Research PublicationPROMISE trial analysis of 3,637 patients: hepatic steatosis tied to 69% higher cardiovascular event risk, mediated partly by noncalcified plaque.
-
Japanese 10-year cohort finds MASLD independent IHD risk
Research PublicationCirculation Reports study of 13,815 adults: MASLD alone predicts ischemic heart disease with HR 1.20.
-
Korean 9.78M cohort confirms CVD risk
Research PublicationGut publishes nationwide Korean data: MASLD carries adjusted CVD hazard ratio of 1.38 over 12.3 years.
-
NAFLD renamed MASLD in Delphi consensus
Definitional ShiftInternational panel replaces 'non-alcoholic fatty liver disease' with 'metabolic dysfunction-associated steatotic liver disease,' reframing it as a metabolic disease.
-
Swedish biopsy cohort links NAFLD to MACE
Research PublicationGut publishes nationwide histology study: 10,422 biopsy-proven NAFLD patients face aHR 1.63 for major cardiovascular events.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1948-present
Framingham Heart Study (1948)
In 1948, researchers recruited 5,209 adults in Framingham, Massachusetts, and began following them for heart disease. The study coined the term 'risk factor' and established that high cholesterol, high blood pressure, and smoking predicted heart attacks years before symptoms appeared.
Then
Produced hundreds of papers documenting how measurable traits predicted cardiovascular outcomes.
Now
Transformed cardiovascular medicine, leading to routine cholesterol and blood pressure screening and, eventually, the statin era decades later.
Why this matters now
Illustrates the typical lag between epidemiological findings and clinical screening adoption: cholesterol was linked to heart disease in the 1950s-60s, but statins and routine screening took until the 1990s.
2018-2023
SELECT trial, semaglutide (2023)
The SELECT trial randomized 17,600 overweight patients without diabetes to semaglutide or placebo and followed them for cardiovascular events. The drug significantly reduced major adverse cardiovascular events in a non-diabetic population.
Then
Became the first GLP-1 trial to show cardiovascular benefit in overweight patients without diabetes.
Now
Demonstrated that a metabolic drug can modify cardiovascular outcomes, supporting the mechanistic link between metabolic dysfunction, liver fat, and heart disease.
Why this matters now
Provides the proof-of-concept that metabolic therapies, which also reduce liver fat, can lower cardiovascular risk — the causal pathway the liver-CVD studies are probing.
June 2023
NAFLD renamed MASLD (2023)
An international Delphi consensus replaced 'non-alcoholic fatty liver disease' (NAFLD) with 'metabolic dysfunction-associated steatotic liver disease' (MASLD). The new definition drops the term 'non-alcoholic' and defines the disease by metabolic dysfunction rather than by exclusion of alcohol use.
Then
Research literature and regulatory documents began shifting to the new terminology.
Now
Reframed fatty liver as a metabolic disease sharing pathways with diabetes and cardiovascular disease, opening the door to the CVD association studies that followed.
Why this matters now
The definitional shift is what made the current line of research coherent: MASLD is now studied as a cardiometabolic condition, not a liver-only one.
Sources
(11)Related Stories
Food quality emerges as key factor in heart health research
New Capabilities
Updated May 29
New study finds apoB blood test beats standard LDL screening
New Capabilities
Updated Jul 7
One-time CRISPR therapy keeps cholesterol lower for a full year in early trial
New Capabilities
Updated 4 days ago
Statins and the evidence gap
New Capabilities
Updated May 29
Coached lifestyle programs improve dementia-risk cognition more than advice alone
New Capabilities
Updated 2 hours ago
New European guidelines urge every heart patient to be tested for kidney disease
Rule Changes
Updated 4 hours ago